{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T15:28:07Z","timestamp":1769268487637,"version":"3.49.0"},"reference-count":38,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2016,3,1]],"date-time":"2016-03-01T00:00:00Z","timestamp":1456790400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["redjournal.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1016\/j.ijrobp.2015.12.019","type":"journal-article","created":{"date-parts":[[2015,12,17]],"date-time":"2015-12-17T21:39:37Z","timestamp":1450388377000},"page":"783-791","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":38,"title":["Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study"],"prefix":"10.1016","volume":"94","clinical-trial-number":[{"clinical-trial-number":"nct01473628","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4301-5811","authenticated-orcid":false,"given":"Marco","family":"Ruella","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7159-7869","authenticated-orcid":false,"given":"Andrea Riccardo","family":"Filippi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Riccardo","family":"Bruna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Di Russo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michele","family":"Magni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniele","family":"Caracciolo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roberto","family":"Passera","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paola","family":"Matteucci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Massimo","family":"Di Nicola","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Corradini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Parvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guido","family":"Gini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Attilio","family":"Olivieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Ladetto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Umberto","family":"Ricardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tarella","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liliana","family":"Devizzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2015.12.019_bib1","unstructured":"Howlader NNA, Krapcho M, Garshell J, et\u00a0al. SEER cancer statistics review, 1975-2011. Available at: http:\/\/seercancergov\/csr\/1975_2011\/2014. Accessed July 1, 2015."},{"key":"10.1016\/j.ijrobp.2015.12.019_bib2","doi-asserted-by":"crossref","first-page":"3368","DOI":"10.1200\/JCO.2011.40.6546","article-title":"Effectiveness of first-line management strategies for stage I follicular lymphoma: Analysis of the National LymphoCare Study","volume":"30","author":"Friedberg","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib3","doi-asserted-by":"crossref","first-page":"288","DOI":"10.6004\/jnccn.2010.0021","article-title":"NCCN clinical practice guidelines in oncology: Non-Hodgkin's lymphomas","volume":"8","author":"Zelenetz","year":"2010","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib4","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1093\/annonc\/mds517","article-title":"ESMO guidelines consensus conference on malignant lymphoma 2011 part 1: Diffuse large B-cell lymphoma (DLBCL), follicular lymphoma (FL), and chronic lymphocytic leukemia (CLL)","volume":"24","author":"Ghielmini","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib5","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/ajh.23372","article-title":"SIE, SIES, GITMO revised guidelines for the management of follicular lymphoma","volume":"88","author":"Zinzani","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib6","doi-asserted-by":"crossref","first-page":"e65156","DOI":"10.1371\/journal.pone.0065156","article-title":"Early stage WHO grade I and II follicular lymphoma treated with radiation therapy alone","volume":"8","author":"Ahmed","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib7","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1200\/JCO.1996.14.4.1282","article-title":"Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University","volume":"14","author":"Mac Manus","year":"1996","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib8","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0360-3016(01)01747-3","article-title":"Long-term results with radiotherapy for stage I-II follicular lymphomas","volume":"51","author":"Wilder","year":"2001","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib9","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1016\/j.ijrobp.2005.08.010","article-title":"Long-term outcome and mortality trends in early-stage, grade 1-2 follicular lymphoma treated with radiation therapy","volume":"64","author":"Guadagnolo","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib10","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.radonc.2011.05.013","article-title":"Reduced dose radiotherapy for local control in non-Hodgkin lymphoma: A randomised phase III trial","volume":"100","author":"Lowry","year":"2011","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib11","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/0360-3016(80)90027-9","article-title":"Improved five year survival after combined radiotherapy-chemotherapy for stage I-II non-Hodgkin's lymphoma","volume":"6","author":"Monfardini","year":"1980","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib12","doi-asserted-by":"crossref","first-page":"2273","DOI":"10.1002\/(SICI)1097-0142(19971215)80:12<2273::AID-CNCR9>3.0.CO;2-V","article-title":"Extended field and total central lymphatic radiotherapy in the treatment of early stage lymph node centroblastic-centrocytic lymphomas: Results of a prospective multicenter study. Study Group NHL-fruhe Stadien","volume":"80","author":"Stuschke","year":"1997","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib13","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/1097-0142(19830701)52:1<1::AID-CNCR2820520102>3.0.CO;2-M","article-title":"A randomized study of radiotherapy versus radiotherapy plus chemotherapy in stage I-II non-Hodgkin's lymphomas","volume":"52","author":"Nissen","year":"1983","journal-title":"Cancer"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib14","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1002\/1097-0142(19930401)71:7<2342::AID-CNCR2820710728>3.0.CO;2-I","article-title":"Adjuvant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy after radiation therapy in stage I low-grade and intermediate-grade non-Hodgkin lymphoma. Results of a prospective randomized study","volume":"71","author":"Yahalom","year":"1993","journal-title":"Cancer"},{"issue":"Suppl 2","key":"10.1016\/j.ijrobp.2015.12.019_bib15","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1093\/annonc\/2.suppl_2.137","article-title":"Stage I-II low-grade lymphomas: A prospective trial of combination chemotherapy and radiotherapy","volume":"2","author":"McLaughlin","year":"1991","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib16","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/BF02990087","article-title":"A British National Lymphoma Investigation randomised trial of single agent chlorambucil plus radiotherapy versus radiotherapy alone in low grade, localised non-Hodgkins lymphoma","volume":"11","author":"Kelsey","year":"1994","journal-title":"Med Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib17","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1007\/s002770000163","article-title":"IDEC-C2B8 (rituximab) anti-CD20 antibody treatment in relapsed advanced-stage follicular lymphomas: Results of a phase-II study of the German Low-Grade Lymphoma Study Group","volume":"79","author":"Feuring-Buske","year":"2000","journal-title":"Ann Hematol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib18","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/ajh.23674","article-title":"Follicular lymphoma: 2014 update on diagnosis and management","volume":"89","author":"Freedman","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib19","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1182\/blood.V97.1.101","article-title":"Rituximab (anti-CD20 monoclonal antibody) as single first-line therapy for patients with follicular lymphoma with a low tumor burden: Clinical and molecular evaluation","volume":"97","author":"Colombat","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib20","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1182\/blood.V99.3.856","article-title":"Monitoring of minimal residual disease after CHOP and rituximab in previously untreated patients with follicular lymphoma","volume":"99","author":"Rambaldi","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib21","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1016\/j.bbmt.2006.07.007","article-title":"Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma","volume":"12","author":"Ladetto","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib22","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1269\/jrr.47.183","article-title":"Rituximab enhances radiation-triggered apoptosis in non-Hodgkin's lymphoma cells via caspase-dependent and - independent mechanisms","volume":"47","author":"Skvortsova","year":"2006","journal-title":"J Radiat Res (Tokyo)"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib23","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1269\/jrr.46.241","article-title":"Pretreatment with rituximab enhances radiosensitivity of non-Hodgkin's lymphoma cells","volume":"46","author":"Skvortsova","year":"2005","journal-title":"J\u00a0Radiat Res (Tokyo)"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib24","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib25","doi-asserted-by":"crossref","first-page":"3759","DOI":"10.1182\/blood-2013-06-507319","article-title":"Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program","volume":"122","author":"Ladetto","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib26","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1200\/JCO.2003.07.111","article-title":"Long-term follow-up of a prospective study of combined modality therapy for stage I-II indolent non-Hodgkin's lymphoma","volume":"21","author":"Seymour","year":"2003","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib27","doi-asserted-by":"crossref","first-page":"3266","DOI":"10.1200\/JCO.1997.15.10.3266","article-title":"IDEC-C2B8: Results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma","volume":"15","author":"Maloney","year":"1997","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib28","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","article-title":"Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program","volume":"16","author":"McLaughlin","year":"1998","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib29","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1016\/S1470-2045(14)70027-0","article-title":"Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial","volume":"15","author":"Ardeshna","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib30","doi-asserted-by":"crossref","first-page":"e1002020","DOI":"10.1371\/journal.ppat.1002020","article-title":"Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases","volume":"7","author":"Wilen","year":"2011","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib31","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2014.59.7534","article-title":"Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: An analysis from the National LymphoCare Study","volume":"33","author":"Casulo","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib32","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1182\/blood.V124.21.1664.1664","article-title":"Event-free survival at 12 months (EFS12) from diagnosis is a robust endpoint for disease-related survival in patients with follicular lymphoma in the immunochemotherapy era [abstract]","volume":"124","author":"Maurer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib33","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1038\/leu.2014.91","article-title":"How we manage follicular lymphoma","volume":"28","author":"Hiddemann","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib34","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1182\/blood.V89.2.724","article-title":"Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting","volume":"89","author":"Corradini","year":"1997","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/S1470-2045(14)70036-1","article-title":"4 Gy versus 24 Gy radiotherapy for patients with indolent lymphoma (FORT): A randomised phase 3 non-inferiority trial","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib36","doi-asserted-by":"crossref","first-page":"3096","DOI":"10.1200\/JCO.2014.56.5853","article-title":"Rituximab extended schedule or re-treatment trial for low-tumor burden follicular lymphoma: eastern cooperative oncology group protocol e4402","volume":"32","author":"Kahl","year":"2014","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib37","doi-asserted-by":"crossref","first-page":"1634","DOI":"10.1182\/blood.V120.21.1634.1634","article-title":"Treatment of early stage nodal follicular lymphoma using involved-field radiation therapy and rituximab: Preliminary results of the Mir Trial (phase II study of the German Low Grade Lymphoma Study Group (GLSG)) [abstract]","volume":"120","author":"Herfarth","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.ijrobp.2015.12.019_bib38","doi-asserted-by":"crossref","first-page":"2637","DOI":"10.1002\/cncr.29372","article-title":"Frontline rituximab monotherapy induction versus a watch and wait approach for asymptomatic advanced-stage follicular lymphoma: A cost-effectiveness analysis","volume":"121","author":"Prica","year":"2015","journal-title":"Cancer"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615268575?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0360301615268575?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,9,12]],"date-time":"2020-09-12T21:57:16Z","timestamp":1599947836000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0360301615268575"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["S0360301615268575"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.019","relation":{},"ISSN":["0360-3016"],"issn-type":[{"value":"0360-3016","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Addition of Rituximab to Involved-Field Radiation Therapy Prolongs Progression-free Survival in Stage I-II Follicular Lymphoma: Results of a Multicenter Study","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2015.12.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}